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Endothelin1 (ET-1) is a 21-amino acid peptide produced by the vascular endothelium under hypoxia, that acts locally as regulator
of vascular tone and inflammation. The role of ET-1 in Plasmodium falciparum malaria is unknown, although tissue hypoxia
is frequent as a result of the cytoadherence of parasitized red blood cell (pRBC) to the microvasculature. Here, we show that
both synthetic and endothelial-derived ET-1 are removed by parasitized RBC (D10 and W2 strains, chloroquine sensitive, and
resistant, resp.) and native haemozoin (HZ, malaria pigment), but not by normal RBC, delipidized HZ, or synthetic beta-haematin
(BH). The eﬀect is dose dependent, selective for ET-1, but not for its precursor, big ET-1 , and not due to the proteolysis of ET-
1. The results indicate that ET-1 binds to the lipids moiety of HZ and membranes of infected RBCs. These findings may help
understanding the consequences of parasite sequestration in severe malaria.
1. Introduction
Plasmodium falciparum (P.f.) infection may evolve into
severe disease if untreated or inadequately treated, caus-
ing an estimated one million deaths annually [1]. The
severe forms of malaria are characterized by the systemic
release of inflammatory cytokines and the cytoadherence
of P.f. parasitized red blood cells (pRBCs) to the vascular
endothelium. This results in the sequestration of pRBCs in
various organs, such as the brain, lung, and placenta, causing
microcirculatory obstruction and subsequent tissue hypoxia,
metabolic disturbances, and multiorgan failure [2–4].
Products of parasite origin, such as haemozoin (HZ,
malaria pigment), contribute to the pathogenesis of severe
malaria by increasing the production of host inflammatory
cytokines and the expression of adhesion molecules on the
endothelium [4–9]. HZ, the detoxification product of haem,
accumulates as insoluble crystals inside the food vacuole
of intraerythrocytic parasites and, once released into the
circulation, is phagocytised by host cells. Both native HZ
and its synthetic analogue, β-haematin (BH), can modulate
phagocyte and endothelial cell functions in vitro [10–12].
The sequestration of pRBC in the microvasculature may
reduce local oxygen tension with increased risk of tissue
hypoxia, hence inducing the transcriptionally regulated
expression of vasoactive substances in order to modulate
the vascular tone. One of these products is endothelin-1
(ET-1), a potent vasoconstrictor agent, which is produced
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by the vascular endothelium in response to various stimuli
including hypoxia and cytokines [13, 14]. ET-1 is a 21-amino
acid long peptide derived from a larger precursor, pre-proET-
1 that is cleaved first to big ET-1 (whose vasoconstrictor
activity is approximately two orders of magnitude lower
than that of ET-1 itself) and then converted to ET-1
by neutral metallo-endopeptidases known as endothelin-
converting enzymes (ECEs). ET-1 exerts various important
biological actions mediated by three receptor subtypes, ET-
A, ET-B, and ET-C, which have been identified in various
human tissues [15].
The expression and/or production of endothelins and
their receptors is increased in several pathological conditions
such as cardiovascular diseases, pulmonary hypertension,
renal failure, and subarachnoid haemorrhage [16–18]. Ele-
vated levels of ET-1 are also associated with serious infectious
diseases, such as bacterial sepsis and trypanosomiasis [19–
21].
The role of ET-1 in falciparum malaria is still con-
troversial and largely unknown. It has been reported that
severe malaria patients have increased plasma levels of big
ET-1 which correlate with the levels of TNF-α, but not
with parasitaemia, fever, or other features of severe infection
[22]. Recently, children with malaria were shown to have
significantly higher plasma levels of ET-1 compared to
healthy controls. However, there was an apparent trend
for those with severe malaria to have lower ET-1 levels
compared to uncomplicated malaria patients, although a
direct relationship with parasitaemia was not evident [23].
In the previous in vitro studies, we observed that pRBC
down modulate the constitutive or hypoxia-induced ET-1
production by microvascular endothelial cells indicating that
pRBC may induce local modifications of the vascular tone
and the inflammatory response [24, 25]. To obtain further
insights on the relevance of ET-1 modulation for severe
malaria, we performed the experiments herewith presented
to identify the parasite product(s) and the mechanism
through which pRBC modulate the production and/or the
activity of ET-1 under normoxic or hypoxic conditions.
2. Materials and Methods
2.1. Cells, Reagents, and Plasmodium falciparum Cultures. A
long-term cell line of dermal microvascular endothelial cells
(HMECs-1) immortalized by SV 40 large T antigen was
kindly provided by Dr. F. Candal, the Center for Disease
Control, Atlanta, GA, USA [26]. Cells were maintained in
MCDB 131 medium (Invitrogen, Milan, Italy) supplemented
with 10% fetal calf serum (HyClone), 10 ng/mL of epider-
mal growth factor (Chemicon), 1 μg/mL of hydrocortisone,
2 mM glutamine, 100 units/mL of penicillin, 100 μg/mL of
streptomycin, and 20 mM Hepes buﬀer, pH 7.4 (EuroClone).
Unless otherwise stated, all reagents were from Sigma
Aldrich, Milan, Italy.
In vitro cultures of P.f. were adapted from Trager
and Jensen [27]. A chloroquine (CQ)-sensitive P.f. strain
(D10) and a CQ-resistant strain (W2) were maintained at
5% haematocrit (human type A RBC) at 37◦C in RPMI
1640 medium (GIBCO BRL) supplemented with 10% heat-
inactivated A+ human plasma, 20 mM Hepes buﬀer pH 7.4
in a standard gas mixture consisting of 1% O2, 5% CO2, 94%
N2.
2.1.1. Preparation of HZ (Native and Delipidized) and β-
Haematin (BH). To isolate HZ, pRBC (4–8% parasitaemia)
were washed twice with serum-free culture medium, resus-
pended to 25% haematocrit, and fractionated on a discon-
tinuous Percoll/4% sorbitol (wt/vol) gradient (0, 40, 80%)
[28]. After centrifugation at 1075 g, HZ was collected at the
top of the gradient, 0–40% interphase, washed three times
with PBS, and stored at −20◦C.
For the preparation of the delipidized HZ, native HZ
was washed 3 times with Tris-HCl buﬀer (10 mM, pH
7.5) and the pellet extracted twice in a mixture of chloro-
form/methanol 2 : 1 (v/v) and twice in chloroform/methanol
1 : 2 (v/v). At the end, the pellet, containing the delipidized
HZ was dried under a flux of nitrogen and resuspended in
Tris-HCl buﬀer.
Synthetic malaria pigment, β-haematin (BH), was syn-
thesized from haematin (Sigma, Milan, Italy) in methanol
as described [29]. The haem content of a weighed amount
of the native or delipidized HZ and BH dissolved in 0.1 M
NaOH was determined by reading the absorbance at 385 nm
(ε385hematin = 6.1× 104 M cm−1) (Soret band).
2.2. HMEC-1 Treatment. HMECs-1 were seeded in qua-
druplicate at 1.5 × 104/well in 96 well flat bottom tissue
culture clusters (Costar, 3596). After overnight incubation,
monolayers were exposed to asynchronous P.f. cultures.
pRBCs were added to the cells at 1% haematocrit with
a parasitaemia ranging between 2 and 4%. Uninfected
RBCs were used as controls in all experiments. In some
experiments, HMECs-1 were exposed to HZ isolated from
the pRBC cultures as described above.
HMECs-1 treated with pRBC or haemozoin were cul-
tured for 24 hours at 37◦C under normoxic (20% O2, 5%
CO2, 75% N2) or hypoxic conditions (1% O2, 5% CO2, 94%
N2) in sealed chambers.
2.3. Quantification of ET-1 and Big ET-1. At the end of each
treatment, plates were centrifuged and ET-1 and big ET-1
peptides quantified in the supernatant using a specific ELISA
test (PANTEC, Torino, Italy). ET-1 was also determined
by a fluorimetric procedure according to Chaloin [30].
Fluorescence spectra were recorded in quarz cuvettes by
a Perkin Elmer LS50 spectrofluorimeter at an excitation
wavelength of 280 nm and the area of the peaks were
calculated by the FLWinLab software. To correct for the
interference on the intensity of the fluorescence caused by the
release of small amounts of haemoglobin during incubation,
control samples were prepared by diluting ET-1 in the
supernatant recovered by centrifugation of a suspension of
normal RBC in PBS.
2.4. RT-PCR Detection of ET-1 mRNA. For mRNA and RT-
PCR analysis, HMEC-1 were seeded at 5× 105/well in 6 well
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plates (Costar, 3516), treated with pRBC or control RBC, and
incubated for 24 hours in normoxic or hypoxic conditions.
At the end of the treatment cells were lysed in 1 mL Trizol
Reagent (Invitrogen). Total RNA was isolated according to
the manufacturer instructions. 1 μg of total RNA was reverse-
transcribed using Superscript First-Strand Synthesis System
(Invitrogen, USA), according to the manufacturer’s protocol.
A portion of cDNA (0.2 μg) was then used as the template
in subsequent PCR amplifications in a total volume of 30 μL
containing 1X buﬀer (Promega), 2.0 mM MgCl2(Promega),
0.2 mM each dNTP, sense and antisense primers (0.2 μM),
and 1.25 Units of Taq thermostable polymerase (Promega).
The sequences of ET-1 specific primers were: forward 5′-
TGC TCC TGC TCG TCC CTG ATG GAT AAA GAG-3′,
reverse 5′-GGT CAC ATA ACG CTC TCT GGA GGG CTT-
3′ (462-bp fragment). G3PDH control primers were: forward
5′-TGA AGG TCG GAG TCA ACG GAT TTG GT-3′, reverse
5′-CAT GTG GGC CAT GAG GTC CAC-3′ CAC (983-bp
fragment). Amplification was performed for 30 cycles and
the annealing temperature was 58◦C. A negative control was
included in each assay to confirm that only cDNA PCR
products were detected and that none of the reagents was
contaminated with cDNA of previous PCR products.
All PCR products were analyzed by electrophoresis
on 1% agarose gels and visualized by ethidium bromide
staining.
2.5. Incubation of ET-1 and Big ET-1 Peptides with RBC of
P.f. Cultures. Diﬀerent concentrations of ET-1 or big ET-1
(5.0, 2.5, 1.2 fmol/mL) (Calbiochem Corp.) were added to
pRBC suspension (2–5% parasitaemia, 2% haematocrit) in
100 μl of HMEC-1 culture medium distributed in 96 well
flat bottom microplates. Control unparasitized RBCs were
maintained for 3-4 days before the experiment in the same
conditions of pRBC (5% haematocrit at 37◦C) and incubated
with ET-1 or big ET-1 as described. After 2, 4, 6, 24 hours
of incubation, plates were centrifuged and supernatants were
collected and assayed for the presence of ET-1 or big ET-1.
ET-1 (5 fmol/mL) was incubated for 24 hours with pRBC
in the presence of the receptor ET-A or ET-B antagonists,
alone or combined, (0.5-0.1 μM) (JKC302 and BQ788, resp.)
(Sigma) or a Protease Inhibitor Cocktail (used at a dilution
of 1 : 200) (P1860 Sigma). ET-1 was then assayed in the
supernatants.
Since parasite cultures are a heterogeneous population
of cells made of pRBC and normal RBC of diﬀerent
density, the total RBC suspension was fractionated onto a
Percoll/4% sorbitol (wt/vol) gradient [28]. This procedure
allows the separation of the HZ containing fraction (top of
the gradient), pRBC (density = 1.078), and three fractions
(young, medium, and old) of unparasitized RBC. Each
fraction was incubated with ET-1 (5–2.5 fmol/mL) for 24
hours after which the residual ET-1 was determined in the
supernatant. Delipidized HZ, BH, or the supernatants of P.f.
cultures were also employed.
When ET-1 was determined by fluorescence spec-
troscopy, normal uninfected RBC, pRBC (D10 strain, 2%
haematocrit) were incubated in PBS in the presence of
ET-1 (10 pmol/mL) for 18 hours, in 2 mL final volume.
Samples were then centrifuged at 600× g for 10 minutes and
supernatants recovered for the fluorimetric analysis.
2.6. Statistical Analysis. All the assays were performed at least
three times in quadruplicate and the results analyzed by the
Student’s paired t-test. Statistical significance was set at P <
.05.
3. Results
3.1. Impaired Recovery of ET-1 Produced by HMEC-1 Cocul-
tured with P.f. pRBC. The constitutive production of ET-
1 by endothelial HMEC-1 cells is significantly increased by
hypoxia. Coincubation of endothelial cells with pRBC (D10
and W2 strains at 2–4% parasitaemia), but not with normal
uninfected RBC, induced a decrease in the levels of ET-
1 detected in the supernatants; no diﬀerences were seen
between the two strains used (Figure 1(a)). The decrease in
ET-1 induced by D10 was dose-dependent (see Figure 1(b)
and previous work [24]) and was not due to inhibition
of ET-1 gene transcription or translation by pRBC since
the level of ET-1 mRNA as well as that of big ET-1, the
precursor of the active peptide ET-1, was not aﬀected in
either normoxic or hypoxic conditions (Figures 1(b) and
1(c)). We also excluded that pRBC may inhibit the processing
of big ET-1 to ET-1 since no accumulation of big ET1 was
seen in the supernatants of endothelial cells incubated with
pRBC.
3.2. Eﬀect of pRBC on Synthetic ET-1 and Big ET-1. Having
determined that pRBC did not interfere with the production
of ET-1 by HMEC-1, we investigated whether pRBCs were
able to bind or degrade synthetic ET-1. The first set of exper-
iments was conducted by incubating diﬀerent concentrations
of commercially available, synthetic ET-1 peptide with pRBC
for 24 hours and measuring the amount of residual ET-1
in the culture medium by ELISA. In the presence of pRBC
(D10 strain, 2–4% parasitaemia), the levels of ET-1 in the
extracellular medium were significantly reduced while big
ET-1, used as control, was not aﬀected (Figure 2(a)). Similar
results were obtained with pRBC from the CQ resistant P.f.
strain W2 (data not shown).
The removal of ET-1 by pRBC was a slow process,
with a significant reduction of ET-1 (60–70% compared to
control) occurring only after 24 hours (Figure 2(b)). ET-
1 levels were not reduced following incubation of ET-1
with uninfected RBC (Figure 2(b)). The decrease of ET-1 in
the presence of pRBC was confirmed using a fluorimetric
method of quantification of ET-1; the data of a representative
experiment are reported in Table 1. A good correlation
(r2 = 0.939) between the % of ET-1 recovery obtained
by the two methods was achieved. The reduction of ET-1
after incubation with pRBC was not due to the enzymatic
degradation of the peptide or to soluble factors released
by pRBC as shown by the experiments conducted in the
presence of protease inhibitors or supernatants from cultures
of diﬀerent P.f. strains (Table 2). This suggests that ET-1 was
not degraded, but likely bound to pRBC membrane.
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Table 1: Absorption of ET-1 by pRBC (D10 strain) or haemozoin: comparison between fluorimetric detection and ELISA assay.
ET-1 recovery
Fluorescence spectroscopy ELISA
Samples Fluorescence Intensity (AUC) % control pmol/mL % control
Controla 41305 9.04
Normal RBC 40503 98.1 8.69 96.1
pRBC (D10 1.6%) 32224 78.0 5.93 65.5
pRBC (D10 3.2%) 30784 74.5 5.03 55.6
Data of a representative experiment out of three experiments performed in the same conditions. ET-1 (10 pmol/mL) was incubated for 18 hours in PBS or in
the presence of normal RBC or pRBC (D10 strain at 1.6% and 3.2% parasitaemia). aControl samples for fluorescence spectroscopy were prepared by diluting
ET-1 in the supernatant recovered by centrifugation of a suspension of normal RBC incubated in PBS for the same length of time. Control samples for ELISA
test were prepared by diluting ET-1 in PBS. At the end of the incubation, RBCs were centrifuged and supernatants used for ET-1 determination by both
methods.
Data are expressed as arbitrary fluorescent units (AUC Area Under the Curve) or as pmol/mL.
Table 2: Eﬀect of normal RBC, pRBC, or supernatants from P. falciparum cultures on the recovery of synthetic ET-1.
% ET-1 recovery when incubated with:
Medium Normal RBC pRBC (D10) pRBC (W2) SN normal RBC SN pRBC (D10) SN pRBC (W2)
ET-1a5 100 91.96 ± 7.2 39.8± 8.3∗ 40.2± 7.5∗ 102 ± 5.4 98 ± 6.3 96 ± 7.8
+proteaseinhibitor 105.7 ± 2.1 101.7 ± 4.8 29.6± 7.3∗ 48.3± 11∗ ND ND ND
a
ET-1 (5 fmol/mL) was incubated for 24 hours in medium or in the presence of normal unparasitized RBC, pRBC from diﬀerent P. falciparum strains or
supernatants (SNs) from parasite cultures. ET-1 was also incubated with RBC or pRBC in the presence of a protease inhibitor cocktail. At the end of the
incubation, ET-1 was detected by ELISA.
Data are expressed as % of ET-1 recovery respect to controls and represent the mean ± SD from three diﬀerent experiments. ∗P < .01 versus control.
To investigate whether ET-1 receptors were involved in
the removal/binding of ET-1 by pRBC, the experiments
were repeated using two receptor antagonists, JKC 302 or
BQ788 which are specific for the ET-A or ET-B receptors,
respectively. As shown in Figure 3, none of the receptor
antagonists (used alone or combined) prevented the removal
of ET-1 by pRBC suggesting that most of the binding
was aspecific. Similar findings were obtained in binding
experiments with radio-labelled ET-1 (125I-ET-1) (data not
shown).
Since parasite cultures are composed by pRBC, normal
RBC of diﬀerent age/density, parasite debris and free HZ,
a Percoll fractionation of the culture was performed, as
previously described [28]. Five diﬀerent fractions were
recovered: young, medium and old normal RBC, enriched
pRBC (mainly at the trophozoite stage) and free HZ. Each
fraction was then incubated with 2.5 fmol/mL of ET-1 for
24 hours. As shown in Figure 4, only the pRBC fraction and
HZ (2 μg/mL) significantly bound ET-1. This demonstrates
that the decrease in the content of ET-1 in HMEC-1 cultures
treated with pRBC (Figure 1) was due to binding of the
released peptide to pRBC and/or HZ.
Native HZ purified from parasite cultures is mainly
made of crystals of dimers of Fe(III) protoporphyrin IX
(haematin), but includes also proteins and lipids of parasite
origin [31, 32]. Since data in the literature suggest that ET-1
interacts by electrostatic forces with neutral phospholipids,
we investigated the role of the lipid fraction in ET-1 binding.
To this purpose, the lipid fraction was removed from native
HZ and the delipidized HZ assayed in the ET-1 adsorption
assay. The haem containing portion of HZ (beta haematin,
BH) was used as control. The experiment was performed by
incubating ET-1 (5 fmol/mL) with diﬀerent concentrations
of native HZ or delipidized HZ or BH. As shown in
Figure 5(a) native HZ removed ET-1 in a dose-dependent
manner, while delipidized HZ or BH had no eﬀect at any of
the doses employed, indicating that the lipid portion, but not
the haem moiety of HZ was involved in ET-1 binding.
To verify whether HZ could bind ET-1 produced by
endothelial cells, HMECs-1 were treated for 24 hours with
diﬀerent concentrations of native HZ. Similarly to pRBC, HZ
reduced the ET-1 levels in a dose-dependent manner both
in normoxic and hypoxic conditions (Figure 5(b)). At the
highest dose use (50 μg/mL), the decrease of ET-1 by HZ
was 87.1% and 83.6% in normoxic or hypoxic conditions,
respectively. As expected, BH did not interfere with ET-1
production by HMEC-1 or recovery.
4. Discussion
The present study provides an evidence that the decrease
in ET-1 caused by P. falciparum-parasitized RBCs is due
by the aspecific binding of ET-1 to pRBCs. The reduction
of ET-1 levels is specific for ET-1 (its precursor, big ET-1
is unaﬀected), is not caused by proteolytic degradation by
soluble products or ET-1 binding to ET-A or B receptors
[33, 34], or inhibition of endothelial cells functions by pRBCs
[24]. The slow reaction kinetics (18–24 hours of incubation
needed for a significant eﬀect to occur) further support this
hypothesis. The aspecific binding of ET-1 to pRBC involves
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Figure 1: Eﬀect of pRBC on the release of ET-1 and big ET-1 from human microvascular endothelial cells (HMECs-1). HMECs-1 were
treated for 24 hours in the presence of normal RBC or pRBC (D10 or W2 strains) at 2–4% parasitaemia in (a), (c), (d) or at the indicated
levels of parisitaemia (b) under normoxic or hypoxic conditions. Supernatants were then assayed for the presence of ET-1 (a, b) or big ET-1
(c) by ELISA. Results represent the mean± SD from five diﬀerent experiments. (a) P = .0014 and P = .0041 D10 versus control in normoxia
and hypoxia, respectively; P = .0017 and P = .0052 W2 versus control in normoxia and hypoxia, respectively; (b) P = .014 and P = .033:
D10 8% and 4% versus control, in normoxia; P = .006,P = .01,P = .027: D10 8%, 4%, and 2% versus control in hypoxia. (d) RT-PCR
analysis of ET-1. G3 PDH served as control. The cells were lysed and mRNA extracted. The PCR products were separated through agarose
gel electrophoresis and visualized by ethidium bromide. The reported data are representative of three independent experiments.
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culture have diﬀerent ability to remove ET-1. Parasite culture
(D10 strain) where density separated by Percoll/sorbitol gradient.
Each fraction was incubated with synthetic ET-1 (2.5 fmol/mL)
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lipids; after density fractionation, only fractions enriched in
pRBC and the HZ containing fraction can bind ET-1, but not
normal RBCs, delipidized native HZ or synthetic BH. ET-1
can be adsorbed by neutral phospholipids via electrostatic
interactions [30].
The process of HZ formation and the modified lipid
composition of the membrane following malaria infection
[28, 35] may explain why ET-1 does not bind to delipidized
HZ or synthetic BH or normal RBCs.
Parasite neutral lipids have recently attracted consider-
able attention as the intracellular environment where crucial
events of the parasite metabolism occur. The detoxification
of haemoglobin-derived haem into HZ crystals seems to
take place in neutral lipid nanospheres within the parasite
food vacuole [36] and diﬀerent neutral lipids associated
with HZ have been identified by ESI-MS/MS. The most
abundant are monostearic and monopalmitic glycerol, with
a small amount of polar lipids such as phosphatidylcholine
or phosphatidylethanolamine. These neutral lipids have been
shown to promote HZ formation by increasing the solubility
of haem monomers [37, 38]. The observation that ET-1
adsorbs to the native HZ, but not to the delipidated HZ
or to BH, strongly argues in favour of the absorption of
ET-1 to the HZ-associated neutral lipids. Likewise, it can
be speculated that ET-1 binds aspecifically to the lipids
of the pRBC membrane. The lipid composition of pRBC
membrane, in particular the phospholipid distribution and
fatty acid pattern, is significantly modified by P. falciparum
[28]. In particular, higher levels of the neutral sphingomyelin
and lower levels of the acidic phosphatidylserine, phos-
phatidylinositol, and phosphatidylethanolamine compared
to normal RBC of the same age/density have been described.
[28, 36]. This phospholipid pattern accounts for the higher
content of palmitic and stearic acid, two saturated fatty
acids shown to be associated with native HZ [36]. Based on
these findings we can speculate that the aspecific binding
of ET-1 to pRBC could be mainly related to the increased
fraction of stearic and palmitic acid due to the diﬀerent
phospholipid pattern of pRBC. Another parasite product,
the glycosylphosphatidylinositol (GPI), that is known to
modulate endothelial cells functions, would be a candidate
for further ET-1 binding studies [39].
The conditions used in these experiments are biologically
sound. pRBC concentrations were 2–4%, and hyperpara-
sitaemia in falciparum malaria is defined as ≥4% pRBCs
in the peripheral blood (locally in the small vessels of the
brain and other target organs it may be much higher). The
HZ concentration of 2 μg/mL is also relevant to biological
8 Journal of Biomedicine and Biotechnology
condition; in fact it has been calculated that ∼3.9 million
trophozoites contain 47 fg of haemozoin per cell with
parasite at 32 hours in the life cycle [32]. Considering a
42% haematocrit, a 0.1% parasitaemia would be suﬃcient to
release 2 μg/mL of haemozoin in vivo.
The clinical findings whereby ET-1 levels are unrelated to
parasitaemia or severity of malaria [23] are not contradictory
but simply hardly relevant to the events occurring in the
small vessels of the target organs (brain, lungs, placenta). ET-
1 action is mainly local [14]. In these vessels, the jamming
of infected and uninfected RBCs will cause hypoxia which
triggers the release of ET-1 by endothelial cells. However,
accumulating pRBCs will increasingly be removing ET-1 and
preventing it from exerting its vasoconstrictive action. The
consequent vasodilation may ameliorate locally the blood
flow but may also contribute to perivascular oedema that
plays a crucial role in the pathogenesis of paediatric severe
malaria and in fatal cases in adults [40, 41]. Cerebral oedema
is a common finding with modern techniques such as the
magnetic resonance imaging (MRI) (T. Taylor, personal
communication). In conclusion, we have shown that ET-1,
but not its precursor, big ET-1, is eﬃciently bound in vitro
by pRBC or HZ through the lipids contained within the HZ
crystals or present in the membrane of pRBC. In vivo, in the
local microenvironment where pRBC sequester, high levels
of ET-1 are likely to be produced, particularly in cerebral
malaria or in the placenta of pregnant women with malaria.
Binding to pRBC or HZ may neutralize ET-1 activity leading
to reduced vasoconstriction and reduced inflammation.
The extent of the decrease in ET-1 bioavailability will be
diﬀerent in diﬀerent areas as function of parasite density
and/or HZ release. As feed back eﬀect, the endothelial cells
will augment the production of nitric oxide (NO) which
is reported to have beneficial eﬀects in murine cerebral
malaria [42].The interaction between host, parasites, and
treatment are complex. The mortality caused by severe
falciparum malaria remains ∼10–25% in spite of eﬀective
antimalarial treatment [43]. Reducing parasitaemia alone
may not be enough to stop or reverse the pathological
processes associated with malaria complications. This means
that, even with reduced parasitaemia with antimalarials,
adjunctive treatments need to be investigated to stop the
progression of disease.
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